# MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

> **NCT00298467** · PHASE2 · WITHDRAWN · sponsor: **Bristol-Myers Squibb** · enrollment: 45 (estimated)

## Conditions studied

- Lymphoma, Large-Cell

## Interventions

- **DRUG:** MDX-060

## Key facts

- **NCT ID:** NCT00298467
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 45 (ESTIMATED)
- **Why stopped:** sponsor decision
- **Last updated:** 2010-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00298467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00298467, "MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00298467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*